Pharmafile Logo
Pharmafocus logo
Advanced Search

Pfizer

Showing 15 posts of 894 posts found.

lilly_building_with_american_flag_web

Lilly’s Verzenio combo tops Pfizer’s Ibrance and is first CDK4/6 inhibitor to show benefit in HR+,HER2- early breast cancer

June 18, 2020
Research and Development Eli Lilly, Pfizer, Verzenio, breast cancer, ibrance

 

News
viagra_tablette

Pfizer and Eli Lilly defeat lawsuit over claims Viagra and Cialis cause cancer

April 9, 2020
Business Services Pfizer, viagra

Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis …

News

Pfizer scores EU approval for MabThera biosimilar Ruxience

April 6, 2020
Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar

The European Commission has moved to authorise Ruxience, Pfizer’s biosimilar version of MabThera (rituximab).  The decision marks the seventh biosimilar …

News
shutterstock_159488225

Bavencio Phase 3 head and neck cancer trial terminated

March 16, 2020
Research and Development, Sales and Marketing Bavencio, Cancer, EMD Serono, Merck KGaA, Pfizer, trial failure

Merck KGaA, its biopharma division EMD Serono, and Pfizer have announced their decision to terminate their ongoing Phase 3 trial …

News
pfizer-building-logo1web

Europe approves first treatment for transthyretin amyloidosis in cardiomyopathy patients: Pfizer’s Vyndaqel

February 19, 2020
Research and Development, Sales and Marketing Europe, Pfizer, Vyndaqel, pharma, transthyretin amyloidosis

The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type …

News

Europe’s CHMP recommends Pfizer’s biosimilar of Roche’s MabThera

February 4, 2020
Manufacturing and Production, Sales and Marketing MabThera, Pfizer, Ruxience, biosimilar, pharma

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has revealed that it has awarded a positive opinion for …

News

Pfizer’s Ibrance combo authorised via the Cancer Drugs Fund for advanced breast cancer

January 15, 2020
Research and Development Cancer Drugs Fund, NICE, Pfizer, ibrance, pharma

NICE, the drug watchdog for England and Wales, has given its approval for Pfizer’s Ibrance (palbociclib) in combination with AstraZeneca’s …

News
biogen_austria_238

Biogen picks up Pfizer’s Phase 1 therapy for Alzheimer’s symptoms in potential $700m deal

January 14, 2020
Manufacturing and Production, Sales and Marketing Alzheimer's, Biogen, Pfizer, pharma

Biogen has entered into an agreement with Pfizer to acquire the latter’s Phase 1 candidate PF-05251749 in order to develop …

News
shutterstock_38078521

Bavencio extends survival at Phase 3 in previously untreated locally advanced or metastatic urothelial carcinoma

January 7, 2020
Manufacturing and Production, Research and Development Bavencio, Merck KGaA, Pfizer, pharma

Bavencio (avelumab), the anti-programmed death ligand-1 (PD-L1) antibody co-developed by Pfizer and Merck KGaA’s biopharma unit EMD Serono, has been …

News

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

News

Pfizer’s Vyndaqel scores CHMP support for transthyretin amyloidosis in cardiomyopathy patients

December 16, 2019
Sales and Marketing Pfizer, Vyndaqel, pharma

Pfizer’s once-daily 61mg oral capsule formulation of Vyndaqel (tafamidis) has secured a positive opinion from the European Medicines Agency’s (EMA) …

News

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

December 9, 2019
Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …

News
pfizer_building_logo1_19

Pfizer’s Ibrance approved by NICE, to be added to the Cancer Drugs Fund

November 28, 2019
Manufacturing and Production, Research and Development Cancer Drugs Fund, NHS, NICE, Pfizer, breast cancer, ibrance, pharma

Today it was announced that the National Institute for Health and Care Excellence (NICE) has recommended Pfizer’s Ibrance (palbociclib) to …

News
shutterstock_79370437

New ICER report reveals most cost-effective rheumatoid arthritis therapies

November 27, 2019
Research and Development, Sales and Marketing AbbVie, Eli Lilly, Humira, Olumiant, Pfizer, Rinvoq, Xeljanz, pharma

The Institute for Clinical and Economic Review (ICER) has unveiled a new report comparing the clinical efficacy and cost-effectiveness of …

News

Pfizer’s Humira biosimilar secures FDA approval, due to launch in 2023

November 18, 2019
Sales and Marketing Abrilada, FDA, Humira, Pfizer, biosimilar, pharma

Pfizer has confirmed the FDA approval of Abrilada (adalimumab-afzb),  its biosimilar version of AbbVie’s Humira, the world’s best-selling drug,   …

News
The Gateway to Local Adoption Series

Latest content

BMS’ Opdivo/Yervoy combination accepted by Scottish Medicines Consortium for colorectal cancer

February 5, 2026

AstronauTx appoints Adam Rosenberg as Chair of the Board

February 5, 2026

Astellas Pharma’s Vyloy accepted by Scottish Medicines Consortium for gastric cancer

February 4, 2026

Angelini Pharma appoints Sergio Marullo di Condojanni as CEO

February 4, 2026

QV Bioelectronics secures £4.5m in funding for brain cancer therapy development

February 3, 2026